Search Results 791-800 of 13435 for Assay

1. A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations - Mayo Clinic

   ... assay (e.g., FoundationOne® CDx or Guardant360® CDx), breakapart fluorescence in situ hybridization (FISH), or other validated assay. Potential participants ...

2. Tests and Procedures - Mayo Clinic

   Featured topics · Cancer · Cardiovascular Diseases and Surgery · Neurology and Neurosurgery · Transplant.

3. Discovery's Edge: Plugging into drug discovery - Mayo Clinic News Network

   D., director of assay development, designed a novel test to find compounds that bind to cyclophilin B. The research team found several hits in molecules ...

4. A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) - Mayo Clinic

   Documentation of an NRAS mutation (tumor tissue or blood) prior to first dose of study drug(s) as determined locally with an analytically validated assay in a ...

5. Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) - Mayo Clinic

   ... assay score (Oncotype RS>25, high risk Mammaprint, PAM-50, EndoPredict or ProSigna score). - Note: Eligibility requires primary tumor size ≥1.0 cm in ...

6. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

   Patient has a pathology report confirming PIK3CA mutant status by a certified laboratory using a validated PIK3CA mutation assay (either from tissue or blood).

7. Hairy Cell Leukemia Clinical Trials - Mayo Clinic Research

   GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study ...

8. Prerequisites and Requirements - M.D. Program - Mayo Clinic Alix School of Medicine

   The preferred method of testing is by Interferon-Gamma Release Assay (IGRA). This lab must be drawn within three months prior to program start ...

9. A Study of KRN23 in Adult Subjects with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome - Mayo Clinic

   Have an FGF23 level ≥ 100 pg/mL by Kainos assay. Have a ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP ...

10. Tests and treatments - Mayo Clinic

    At Mayo Clinic, you have access to the latest advances and proven innovations for diagnosing and treating cancer. Not all services are provided at all ...